BG
Bunge Global S.A.
BG's fundamentals are mixed, but it looks expensive: trading at 17x earnings, about twice its usual 9.2x. Analysts expect strong earnings growth.
BG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Weak |
BG's revenue is currently healthy, and its profitability is stable, but its cash flow and balance sheet are under pressure.
BG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7x | $41.36 | -59% |
| Fair | 9.2x | $54.65 | -45% |
| Forward | 9.3x | $99.98 | — |
| Expensive | 16x | $97.75 | -2.2% |
| Current | 17x | $99.98 | — |
Historical ranges are pointers, not guarantees.
BG's PE is in its expensive range at 17x. If earnings grow as analysts expect, today's price would be 9.3x next year's earnings, in its fair range.
BG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BG, with profitability improving.
BG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.80 | +81% |
| Q3 2026 | $5.95 | -36% |
| Q2 2026 | $5.15 | -49% |
| Q1 2026 | $4.29 | -46% |
| Q4 2025 | $5.42 | -33% |
| Q3 2025 | $9.29 | +18% |
| Q2 2025 | $10.01 | +14% |
| Q1 2025 | $7.88 | -37% |
| Q4 2024 | $8.08 | -46% |
BG's earnings per share have fallen from their peak: $5.95 over the past year, against $15.91 in late 2021.
BG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $23.8B | +7.4% |
| Q2 2026 | $24B | +88% |
| Q1 2026 | $21.9B | +88% |
| Q4 2025 | $23.8B | +75% |
| Q3 2025 | $22.2B | +72% |
| Q2 2025 | $12.8B | -3.6% |
| Q1 2025 | $11.6B | -13% |
| Q4 2024 | $13.5B | -9.3% |
BG's revenue has grown year over year for five quarters in a row: $23.8B last quarter, up 7.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.2% | +0.9 points |
| Q2 2026 | 3.9% | 0 points |
| Q1 2026 | 0.3% | -2.2 points |
| Q4 2025 | 0.4% | -5 points |
| Q3 2025 | 1.2% | -1.3 points |
| Q2 2025 | 3.9% | +3.1 points |
| Q1 2025 | 2.4% | -0.3 points |
| Q4 2024 | 5.4% | N/A |
BG's operating margin was 2.2% last quarter, up 0.9 points from the same quarter a year ago.
BG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -505% |
| Q2 2026 | -$1B | +$450M |
| Q1 2026 | -$877M | -$282M |
| Q4 2025 | $809M | +43% |
| Q3 2025 | $385M | -60% |
| Q2 2025 | -$1.5B | +$293M |
| Q1 2025 | -$595M | -178% |
| Q3 2024 | $973M | -13% |
BG has burned cash in most quarters: −$2.7B over the past year, against −$1.1B the year before.
BG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -1.3M shares |
| 1 year | -2.2% | -4.4M shares |
| 3 years | +28% | +42.8M shares |
| 5 years | +27% | +41.5M shares |
| Available history | +37% | +52M shares |
BG has 194M diluted shares, down 2.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2023 | $466M |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
BG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.3x | High |
| Q2 2026 | 6.3x | High |
| Q1 2026 | 7.9x | High |
| Q4 2025 | 7.0x | High |
| Q3 2025 | 6.0x | High |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.8x | Healthy |
| Q4 2024 | 1.5x | Healthy |
BG's net debt is about 6.3 years of its operating earnings (EBITDA), up from 6.0 years a year ago.
BG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.8 | Neutral |
| Stochastic | 16.5 | Oversold |
BG's weekly RSI is 41 (neutral) and its Stochastic is 17 (oversold).
BG PE vs Consumer Defensive Sector
| Metric | BG | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 19x | 14% below |
| PE % | 84 | 18 | 66 pts above |
BG is trading at 17x earnings, a 14% discount to the Consumer Defensive sector's median of 19x.
BG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $102.9 | 2.9% below |
| 20 week MA | $109.9 | 9.1% below |
| 50 week MA | $113.1 | 12% below |
| 100 week MA | $97.0 | 3.1% above |
| 200 week MA | $98.2 | 1.8% above |
BG has slipped below its 8-, 20- and 50-week averages, though it's still 1.8% above its 200-week average.
BG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $57.4 | $64.3 | +12% |
| 2021 | $64.3 | $90.2 | +40% |
| 2022 | $90.2 | $99.0 | +9.8% |
| 2023 | $99.0 | $101.0 | +2% |
| 2024 | $101.0 | $78.1 | -23% |
| 2025 | $78.1 | $89.1 | +14% |
| 2026 YTD | $89.1 | $100.0 | +12% |
BG has finished higher in five of the last six years. It's up 12% so far in 2026.